Tobira Therapeutics

Tobira Therapeutics is a privately held company based in South San Francisco, California. The company employs a team of 4 individuals and has generated revenue exceeding $10,000. Tobira Therapeutics focuses on developing and commercializing innovative therapeutics for a range of diseases, including liver disease, human immunodeficiency virus (HIV-1), fibrosis, and inflammation. Their lead product candidate, cenicriviroc (CVC), is a proprietary immunomodulator with potential applications in treating non-alcoholic steatohepatitis (NASH), kidney fibrosis, HIV-1, and other conditions. CVC is a once-daily pill with a demonstrated safety and tolerability profile established in clinical trials involving 550 subjects, including 115 HIV-1 infected individuals treated for up to 48 weeks. Tobira plans to initiate a Phase 2 clinical trial for CVC in NASH in the second half of 2014. The company believes CVC holds unique potential in targeting the immuno-inflammatory pathways responsible for fibrosis in NASH, a space where it is currently the only product candidate in development. Additionally, CVC is Phase 3-ready for HIV-1 infection, with potential as a foundational component in fixed-dose combination therapy. Visit Tobira Therapeutics at tobiratherapeutics.com to learn more.